Skip to content
Screener

Accrued Expenses at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$220.51M+84.7%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$1.42M-79.3%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$7.75M+2.7%
XER
Xeris Biopharma Holdings, Inc.XERS
$4.98M+205%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$1.25M+106%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$316.87M+2.2%

Other financials

Income statement

See full
Operating income-$2.0M+61.2%
Net income-$2.5M+49.6%
EPS (diluted)-$0.05+54.5%

Balance sheet

See full
Cash & equivalents$3.1M+1,132%
Total equity$2.5M-41.5%
Total assets$3.5M

Cash flow

See full
Operating cash flow-$2.1M-191%

Valuation

See full
Market cap$111.66M-89.5%

Returns & leverage

See full
Return on equity-1,209.8%
Current ratio3.5×

Where this comes from

Reported directly by Polaryx Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.

The source filing: Polaryx Therapeutics, Inc.’s 10-K, filed March 24, 2026.

Filed
Mar 24, 2026, 12:00 AM EDT
Fiscal year
FY2025
Accession
0001213900-26-033064
Line itemDecember 31, 2025December 31, 2024
Accrued research and development expenses$86
Accrued employee-related expenses211
Accrued expenses$21$87

Item 8. Financial Statements and Supplementary Data

FAQ

What is Polaryx Therapeutics, Inc.'s accrued expenses?
Polaryx Therapeutics, Inc. (PLYX) reported accrued expenses of $21K in Q4 2025.
What does accrued expenses mean?
Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.

Ask your AI about Polaryx Therapeutics, Inc.'s accrued expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude